Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392)

Market Cap	90.79B
Revenue (ttm)	2.49B
Net Income (ttm)	-294.04M
Shares Out	1.27B
EPS (ttm)	-0.23
PE Ratio	n/a
Forward PE	151.17
Dividend	0.32 (0.44%)
Ex-Dividend Date	Jun 3, 2024

Volume	3,465,488
Open	72.05
Previous Close	72.14
Day's Range	71.51 - 72.62
52-Week Range	46.30 - 89.89
Beta	2.20
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 18, 2025

About Beijing Wantai Biological Pharmacy Enterprise

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. research, develops, produces, distributes, and sells infectious disease diagnostic reagents and vaccines in China and internationally. The company provides chemiluminescence series, assembly line series, nucleic acid series, dry type fluorescent immunoassay, and fully automatic blood type analyzer and reagents; ELISA kits; rapid diagnosis; bole series; and supporting reagents. The company was founded in 1991 and is headquartered in Beijing, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1991
• Employees: 3,843
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603392

Financial Performance

In 2023, Beijing Wantai Biological Pharmacy Enterprise's revenue was 5.51 billion, a decrease of -50.73% compared to the previous year's 11.19 billion. Earnings were 1.25 billion, a decrease of -73.65%.